Search

Displaying results 9591 - 9600 of 10000 in total
  1. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  2. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  3. Drug

    Motexafin gadolinium

    go.drugbank.com/drugs/DB05428
    Investigational

    Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to t...

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  5. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.

  6. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  7. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    AVI-4557

    go.drugbank.com/drugs/DB05447
    Experimental

    AVI-4557 is therefore indicated to limit toxicity for patients receiving highly-toxic therapeutic drugs for treatment of anxiety, cancer, and a number of other serious conditions. … AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently

  9. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. … FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species.

  10. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    PH-284 belongs to a new family of new chemical entities called vomeropherins. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.